Form 4: Bicara Therapeutics COO Exercises Options, Sells Shares

Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Summary

• Ryan Cohlhepp, President and COO, and a Director of Bicara Therapeutics Inc. (BCAX), engaged in transactions on December 15, 2025.
• He exercised 8,000 stock options at an exercise price of $3.7898 per share.
• Concurrently, he sold a total of 12,500 shares of common stock at a weighted average price of $18.6838 per share.
• The sales were executed in multiple transactions with prices ranging from $18.55 to $18.88.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on February 12, 2025.
• Following these transactions, Cohlhepp beneficially owns 189,141 shares of common stock and 141,334 stock options.

Sentiment

Score: 6

Explanation: The transactions, involving both option exercise and subsequent share sales, were conducted under a pre-arranged Rule 10b5-1 trading plan. This indicates the sales were scheduled in advance and not driven by new, non-public information, which generally reduces the negative sentiment associated with insider selling. The executive is realizing value from vested options.

Positives

• The exercise of stock options indicates the executive is realizing value from previously granted equity compensation.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, suggesting the sales were not based on new, non-public information.

Negatives

• The sale of 12,500 shares by a key executive could be perceived negatively by some investors, as it reduces their direct ownership stake.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: May view the executive's sale of shares with slight concern, though mitigated by the 10b5-1 plan. The executive still retains a significant holding.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

The filing details a routine insider transaction under a pre-arranged 10b5-1 plan, which is a common practice for executives to manage their equity compensation. While there's an insider sale, the pre-scheduled nature means it doesn't signal new information about the company's prospects. Therefore, this specific filing alone does not provide a strong basis for a "buy" or "sell" recommendation, and a "hold" stance is appropriate, pending further fundamental analysis of the company's operations and financial performance.

Keywords

Bicara Therapeutics, BCAX, Ryan Cohlhepp, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation